DAIICHI SANKYO COMPANY, LIMITED

DAIICHI SANKYO COMPANY, LIMITED

R&D Day 2020

December 15, 2020

Sunao Manabe
President and CEO

Antoine Yver, MD, MSc
Executive VP & Global Head, Oncology R&D

PLAY LIST

from the beginning

R&D Day 2020
@
@
@
@
@
@
Delivering the science patients deserve
@
  • 1 Our scientific and competitiveenvironment
@
@
@
@
@
  • 2 Our clinical-stage DXd ADCs
  • ・DS-8201/trastuzumab deruxtecan(T-DXd)
@
@
@
@
@
@
@
@
@
@
@
@
@
@
@
@
@
@
@
@
@
@
@
@
@
@
@
  • ・DS-1062/datopotamabderuxtecan(Dato-DXd)
@
@
@
@
@
@
  • ・U3-1402/patritumabderuxtecan(HER3-DXd)
@
@
@
@
@
@
@
@
@
@
  • ・Alpha: DS-7300 (B7-H3), DS-6157 (GPR20), DS-6000 (CDH6), DS-3939 (TA-MUC1)
@
@
  • 3 Our transformation towards being abiologics & multi-modality Company
@
@
@
@
@
Q&A Consecutive interpretation:Japanese→English
  • Q&A 1
  • Q&A 2
  • Q&A 3
  • Q&A 4
  • Q&A 5
  • Q&A 6
  • Q&A 7
  • Back
  • Next

Download

  • Presentation File(PDF 3.7 MB)
  • Questionnaire Please answer the questionnair
  • Forward-Looking Statements
    System Requirements
GreenPower
link corporate communications